University of California San Francisco

Norah Terrault - 144
Norah
Terrault
MD, MPH

Professor of Clinical Medicine & Surgery
Departments of Medicine & Surgery
Director of Viral Hepatitis Research in Liver Transplantation

Address

513 Parnassus Avenue, MSB, #001
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-476-2227
Fax: 415-476-0659

    Biography

    Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.

    Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.

    Education

    Institution Degree Dept or School End Date
    University of California, San Francisco Post-Doc Fellow/Scholar Medicine 1995
    University of Alberta M.D. School of Medicine 1987
    University of California, San Francisco Residency
    University of California, San Francisco Clinical Fellowship Gastroenterology

    Board Certifications

    American Board of Internal Medicine, Internal Medicine

    American Board of Internal Medicine, Gastroenterology

    Clinical Expertise

    Alcoholic Liver Disease
    Autoimmune Hepatitis
    Benign Liver Tumors
    Cirrhosis
    Fulminant Hepatic Failure
    Hepatitis B
    Hepatitis C
    Hepatocellular Carcinoma (Liver Cancer)
    Live Donor Liver Transplantation
    Liver Transplantation
    Nonalcoholic Fatty Liver Disease
    Pancreas Transplantation
    Primary Biliary Cirrhosis
    Primary Sclerosing Cholangitis

    Clinical Trials

    1. Related Conditions: Hepatitis C, Viruses, Hepatocellular Cancer, Liver Cancer, Hepatitis, Cirrhosis, Liver Transplant, Hepatitis A| Start Date: | End Date:

    Program Affiliations

    UCSF Liver Center

    In the News

    December, 20, 2014 | UCSF Transplant Surgery

    Grants and Funding

    • USC Cirrhosis Clinical Center | NIH | 2021-09-22 - 2026-08-31 | Role: Principal Investigator
    • Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) | NIH | 2002-06-15 - 2024-06-30 | Role: Principal Investigator
    • Hepatitis B Research Network (HBRN): Natural History and Treatment Studies | NIH | 2008-09-30 - 2021-05-31 | Role: Principal Investigator
    • Bay Area Hepatitis C Cooperative Research Center | NIH | 2010-06-15 - 2016-05-31 | Role: Co-Investigator
    • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
    • Resistance to Antiviral Therapy in Chronic Hepatitis C | NIH | 2001-08-01 - 2007-04-30 | Role: Principal Investigator

    Research Narrative

    My research focuses on the natural history and treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), particularly in special populations, including those undergoing liver transplantation. Work in progress addresses the natural history of post-transplant disease and specific therapies to prevent infection or modify HCV and HBV disease progression and loss of grafts from recurrent disease.

    Our virological analyses are focused on characterization of viral mutations that occur in liver transplant recipients receiving antiviral therapies and assessment of the effect of these variant viruses on the natural history and severity of disease post-transplantation. Knowledge of these factors may allow improved organ allocation by identifying subsets of patients with HCV recurrence in liver grafts who would be favorable or unfavorable candidates for retransplantation. 

    Research Interests

    Liver Injury and Repair

    Hepatitis B virus (HBV)

    Hepatitis C virus (HCV)

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 421
    1. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
      Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB| | PubMed
    2. Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.
      Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS, Hepatitis B Research Network (HBRN), Harvard Consortium| | PubMed
    3. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.
      Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, Terrault N, Nonalcoholic Steatohepatitis Clinical Research Network| | PubMed
    4. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
      El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, McHutchison J, Brainard DM, Terrault N, Curry MP| | PubMed
    5. The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome.
      Sarkar M, Terrault N, Duwaerts CC, Tien P, Cedars MI, Huddleston H| | PubMed
    6. Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.
      Wang GP, Terrault N, Reeves JD, Liu L, Li E, Zhao L, Lim JK, Morelli G, Kuo A, Levitsky J, Sherman KE, Frazier LM, Ramani A, Peter J, Akuskevich L, Fried MW, Nelson DR| | PubMed
    7. Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?
      Zhou K, Terrault N| | PubMed
    8. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
      Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z, HCV-TARGET Study Group| | PubMed
    9. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
      Campos-Varela I, Agudelo EZ, Sarkar M, Roberts JP, Terrault NA| | PubMed
    10. Prevalence and Predictors of Patient-Reported Long-term Mental and Physical Health After Donation in the Adult-to-Adult Living-Donor Liver Transplantation Cohort Study.
      Dew MA, Butt Z, Liu Q, Simpson MA, Zee J, Ladner DP, Holtzman S, Smith AR, Pomfret EA, Merion RM, Gillespie BW, Sherker AH, Fisher RA, Olthoff KM, Burton JR, Terrault NA, Fox AN, DiMartini AF| | PubMed